Latest Healthcare News

Wellnex Life announces the resignation of joint CEO George Karafotias, with Zack Bozinovski stepping up as sole CEO. The company plans to repay a $705,000 director loan within 90 days.

EMVision Medical Devices has been awarded a $3 million non-dilutive government grant to conduct a pioneering clinical study using its telehealth-enabled emu™ brain scanner in regional South Australia, aiming to transform stroke diagnosis and treatment.

Cochlear Limited has extended its on-market share buy-back program, allowing the company to repurchase up to AUD 75 million of its fully paid ordinary shares until August 2026.

Cochlear Limited reported a solid FY25 with 4% revenue growth and a 1% rise in underlying profit, underpinned by new product launches and expanding evidence linking implants to reduced dementia risk. The company’s FY26 outlook signals further gains as it advances market leadership and innovation.

Cochlear Limited reported a 4% revenue rise in FY25, driven by strong implant sales and launched the world’s first smart cochlear implant system. The company forecasts up to 17% profit growth in FY26, underpinned by innovation and expanding markets.

Cochlear Limited has announced a fully franked ordinary dividend of AUD 2.15 per share for the six months ending June 2025, payable in October with multi-currency options for shareholders.

Cochlear Limited has reported steady financial growth with a 4% rise in sales revenue and a 9% increase in underlying net profit for the fiscal year ending June 2025, maintaining its dividend payout.

TALi Digital Limited reported a sharp reduction in losses for FY25 alongside a strategic acquisition of YCDI Education Australia, signaling a pivot towards social-emotional learning. The company also secured nearly $1 million in fresh capital to support its growth ambitions.

Nyrada Inc has responded to ASX inquiries confirming the timely and compliant disclosure of positive safety data from its Phase I clinical trial of Xolatryp. The company detailed the timeline of its awareness and release of information, affirming adherence to continuous disclosure rules.

Pro Medicus Limited has announced a fully franked ordinary dividend of AUD 0.30 per share for the fiscal year ending June 30, 2025, signaling steady returns for shareholders.

Pro Medicus Limited has delivered a record-breaking FY2025 with soaring profits and a wave of major US healthcare contracts, setting the stage for continued expansion.

Pro Medicus Limited has reported a robust FY25 with revenue climbing nearly 32% and net profit up 39%, prompting a significant dividend increase.